Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer

Immunotherapy and tumor microenvironment

(2016) Haidong Tang et al.   CANCER LETTERS

PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas

(2016) Ashley Cimino-Mathews et al.   HUMAN PATHOLOGY

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

(2016) Rita Nanda et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes

(2015) H. R. Ali et al.   ANNALS OF ONCOLOGY

The lymph node pre-metastatic niche

(2015) Jonathan P. Sleeman   JOURNAL OF MOLECULAR MEDICINE-JMM

Erratum: Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer

(2015) Sidra Nawaz et al.   MODERN PATHOLOGY

Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases

(2015) Hojabr Kakavand et al.   MODERN PATHOLOGY

Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy

(2015) Abhisek Swaika et al.   MOLECULAR IMMUNOLOGY

The lymph node microenvironment and its role in the progression of metastatic cancer

(2015) Ethel R. Pereira et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer

(2015) Tao Qin et al.   Oncotarget

Prognostic and predictive value of PDL1 expression in breast cancer

(2015) Renaud Sabatier et al.   Oncotarget

Changes in glycoprotein expression between primary breast tumour and synchronous lymph node metastases or asynchronous distant metastases

(2015) Emila Kurbasic et al.   Clinical Proteomics

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

(2014) R. Salgado et al.   ANNALS OF ONCOLOGY

T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands

(2014) Pinar Karasar et al.   BREAST CANCER RESEARCH AND TREATMENT

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

(2014) S. Muenst et al.   BREAST CANCER RESEARCH AND TREATMENT

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

(2014) K. A. Schalper et al.   CLINICAL CANCER RESEARCH

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases

(2014) L.B. Jilaveanu et al.   Journal of Cancer

PD-L1 Expression in Triple-Negative Breast Cancer

(2014) E. A. Mittendorf et al.   Cancer Immunology Research

The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer

(2013) S. Muenst et al.   BREAST CANCER RESEARCH AND TREATMENT

Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis

(2013) Zi-xiang Yao et al.   MEDICAL ONCOLOGY

Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer

(2012) Aleksandra Markiewicz et al.   Journal of Translational Medicine

Nodal Status and Clinical Outcomes in a Large Cohort of Patients With Triple-Negative Breast Cancer

(2011) Leonel F. Hernandez-Aya et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

(2011) M. Dowsett et al.   JNCI-Journal of the National Cancer Institute